Introduction
Recent identification of various tumor-associated antigens (TAAs) has encouraged the clinical development of cell-mediated immunotherapy for leukemia targeting leukemia-associated antigens.
1,2 Among various kinds of immunotherapy, adoptive tumor-specific T-cell therapy using ex vivo expansion of autologous tumor-responsive T cells seems to be an attractive option. Indeed, patients with advanced metastatic melanoma have been treated successfully with melanoma-specific T cells obtained from tumor-infiltrating T cells (TILs). [3] [4] [5] Although adoptive transfer of tumor-specific TILs is a promising strategy, its general application for therapy would appear to be unlikely due to the complex procedures and difficulties involved in the timely preparation of sufficient numbers of tumor-specific cytotoxic T lymphocytes (CTLs) with adequate therapeutic quality. 6, 7 To address these problems, an innovative approach involving substituting redirected T cells using predefined tumor antigen-specific T-cell receptor (TCR) gene transfer has been developed. In recent clinical trials, melanoma antigen-specific TCR gene-transferred T cells have been employed for treatment of patients with advanced melanoma. 8, 9 However, the clinical efficacy of TCR gene-engineered T cells is still not satisfactory, and serious autoimmune responses have been observed in some melanoma patients. In addition, adoptive immunotherapy using tumor antigen-specific TCR gene-transferred T cells targeting malignancies other than melanoma still remains in its infancy. Therefore, the development of TCR gene-immunotherapy targeting universal TAAs is essential in order to popularize this strategy for cancer treatment.
Wilms' tumor gene product 1 (WT1) is one of the zinc-finger transcriptional regulators that is abundantly expressed in the vast majority of acute leukemias, but not and other groups to develop adoptive T-cell immunotherapy targeting leukemia stem cells using WT1-specific TCR gene transfer. [15] [16] [17] In order to facilitate the clinical application of adoptive immunotherapy using genetically engineered WT1-specific CTLs, some important issues need to be addressed.
First, there is the problem of mispairing between endogenous and introduced TCR chains that would reduce the expression of introduced TCR on the surface of gene-modified T cells, resulting in lower functionality. 18 Mispairing of TCR could also carry a risk of evoking severe autoimmunity. 19, 20 Therefore, it is essential to clarify both the on-and off-target adverse effects mediated by WT1-TCR gene-engineered T cells using in vivo as well as in vitro systems. The other issue of concern is bone marrow suppression mediated by WT1-specific T cells, because it has been reported that hematopoietic progenitor cells express WT1 mRNA. 21, 22 In previous trials of WT1 peptide vaccine, suppression of normal hematopoiesis has not been reported in most cases, even though WT1-specific CTLs were generated following vaccination.
23,24
However, long-term adverse effects on hematopoietic progenitors mediated by adoptively transferred WT1-TCR gene-engineered T cells should be considered, because in this therapy, a larger number of WT1-specific T cells are infused at one time into patients.
To overcome the above problems, we have recently developed a novel retroviral begin. In the present study, with the aim of clinically applying this WT1-siTCR gene transfer system for treatment of leukemia, we assessed in detail the efficacy and safety of adoptive immunotherapy using WT1-specific TCR gene-modified CTLs using both in vivo as well as in vitro experimental systems. On the basis of the data we have obtained, we discuss the feasibility of this novel gene-immunotherapy for leukemia using a WT1-siTCR retroviral vector.
Methods

Cloning of WT1-specific TCR gene and construction of WT1-TCR retroviral vectors
The HLA-A*24:02-restricted and WT1 235-243 -specific TCR-α and TCR-β genes were cloned from our originally established CTL clone, TAK-1, using the 5' RACE method (Clontech, Mountain View, CA). 27 The TCR-α and TCR-β genes of TAK-1 appeared to be Vα20/J33/Cα and Vβ5.1/J2.1/Cβ2, respectively. Retrovirus vectors expressing
For personal use only. on April 2, 2017. by guest www.bloodjournal.org From 6 TAK-1-derived TCR (WT1-TCR) genes were constructed as reported previously. 25 Briefly, the WT1-TCR-α and TCR-β genes were bicistronically integrated into a conventional MS-bPa retroviral vector (WT1-coTCR vector).
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Partially codon-optimized TCR-α and TCR-β genes were similarly integrated into a novel MS-bPa-based retroviral vector encoding shRNAs that complementarily bind to the constant regions of the endogenous TCR-α and TCR-β genes (WT1-siTCR vector) (Supplemental figure 1) . Ecotropic retroviral vectors were obtained by transient co-transfection of WT1-TCR-expression retroviral vector and other components (Takara Bio, Otsu, Japan) to HEK293 cell line, and subsequently GaLV-pseudotyped retroviral vectors were obtained by sequential infection of ecotropic retroviral vectors to PG13 cell line. The Jurkat/MA cell line, lacking endogenous TCR and engineered with the hCD8α and NFAT-luciferase construct, 29 was transduced with the WT1-TCR vector to confirm that our retroviral vector was actually able to express functional WT1-specific and HLA-A*24:02-restricted TCR molecules on the cell surface (Supplemental figure   2 ). 5'-TATTGCAGCCTGGGTAAGCACA-3' (Takara Bio). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA as an internal control was prepared as described previously. 30 These samples were analyzed using an ABI Prism 7500 Sequence Detection System (Applied Biosystems, Foster City, CA). The expression level of WT1 mRNA was corrected by reference to that of GAPDH mRNA, and the amount of WT1 mRNA in each sample relative to that in the K562 leukemia cell line, which strongly expresses WT1 mRNA (shown as 1.0), was calculated by the comparative ΔCt method.
Cell lines, freshly isolated leukemia cells, and normal cells
In vivo anti-leukemia effect of WT1-siTCR gene-transduced CTLs
Six-week-old NOD/scid/γc null (NOG) female mice 35 were purchased from the Central Institute for Experimental Animals (Kawasaki, Japan) and maintained in the institutional animal facility at Ehime University. All in vivo experiments were approved by the Ehime University animal care committee. For xenografting of human leukemia cells, NOG mice were inoculated subcutaneously in the left flank with 5x10 6 K562-A*24:02 cells, which had been pre-incubated with 2.5x10 7 effector cells for 5
hours. Then, 1x10 7 effector cells were additionally administered intravenously via the tail vein every week for a total of 5 times. The mice were monitored for tumor growth and survival after inoculation; the tumors were measured at 5-day intervals, and the tumor area was determined.
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In vivo differentiation of human hematopoietic stem cells in humanized mice
CD34
+ cells were isolated from CBMCs (hCB-CD34 + cells), and then 5x10 4 of the cells were co-incubated with 2.5x10 5 autologous WT1-siTCR-transduced or non-gene-modified CTLs generated from cord blood CD8 + T cells for 5 hours.
hCB-CD34 + cells were then re-isolated from the cell mixture, and injected intravenously into 7-week-old NOG mice that had been irradiated with 1.5 Gy. Three months later, these mice were sacrificed in order to study the engraftment and differentiation of human hematopoietic cells in both the bone marrow and spleen. Human leukocytes were discriminated from murine cells using anti-hCD45 MoAb (Becton Dickinson).
Human cells were further stained with MoAbs against cell lineage-related surface molecules, including CD3, CD8, CD4, CD19, CD33, CD34, CD38, CD41a, and GPA (Becton Dickinson). The expression of HLA-A*24:02 in the engrafted human cells was also measured using FITC-conjugated anti-HLA-A24 MoAb (One Lambda, Canoga Park, CA), and the immunostained cells were analyzed using a Gallios flow cytometer and FlowJo software.
Results
Comparison of WT1-TCR expression and WT1-specific cytotoxic reactivity of WT1-siTCR-and WT1-coTCR-transduced CD8 + T cells
First, we confirmed the augmented and inhibitory efficacies of the WT1-siTCR vector for expression of the respectively introduced and endogenous TCRs. In order to do so, we transduced WT1-siTCR into HBZ-1, which is an HLA-A*02:01-restricted and Figure 1A , positivity for HLA-A*24:02/WT1-tetramer staining in non-treated, WT1-coTCRand WT1-siTCR-transduced HBZ-1 was less than 1%, 29%, and 65%, respectively, whereas the corresponding values for HLA-A*02:01/HBZ-tetramer staining were 98%, 20% and 4%, respectively. For functional assessment of the efficacy of the siTCR vector for suppression of endogenous HBZ-TCR, CD107a assays were performed. We evaluated the extent of the decreased responsiveness to the cognate HBZ peptide mediated by WT1-coTCR-and WT1-siTCR-transduced HBZ-1 in comparison with that mediated by the parent HBZ-1. As shown in Figure 1B , WT1-siTCR-transduced HBZ-1 exhibited an apparent loss of responsiveness to the HBZ peptide-loaded T2 cells, indicating that sufficient functional suppression of endogenous TCR is achievable using the WT1-siTCR vector. The reactivity of WT1-coTCR-transduced HBZ-1 to stimulation with HBZ peptide also appeared to decrease in comparison with that of the parental HBZ-1 clone; however, the inhibitory effect of the siTCR vector appeared to be higher than that of the coTCR vector at high concentrations of the HBZ peptide. On the basis of these data, we were able to confirm the efficacy of the WT1-siTCR vector for augmentation of introduced TCR expression and inhibition of endogenous TCR expression.
Next, we further investigated whether enhanced expression of the introduced TCR by the WT1-siTCR vector actually up-regulated the function of engineered CD8 + T cells. In order to do this, we compared the amounts of intracellular IFN-γ production and degrees of granular exocytosis by WT1-coTCR-and WT1-siTCR-transduced CD8 + T cells in response to stimulation with WT1 peptide. As shown in the upper column of Figure 1C , the proportion of tetramer-positive cells in WT1-siTCR-transduced CD8 + T cells was Similarly, as shown in Figure 1D , up-regulation of cytotoxicity mediated by WT1-siTCR-transduced CD8 + T cells against both WT1 peptide-loaded target cells and HLA-A*24:02-positive leukemia cells was detected as compared with that mediated by WT1-coTCR-transduced CD8 + T cells.
Enhanced expandability without deterioration of antigen-specific responsiveness of WT1-siTCR-transduced CD8 + T cells
Efficient expansion of transferred T cells in vivo as well as in vitro is an important
issue affecting the efficacy of adoptive T-cell therapy. Therefore, we compared the expandability of WT1-siTCR-transduced and WT1-coTCR-transduced CD8 + T cells following repeated stimulation with WT1 peptide. Representative data are shown in Figure 2A . WT1-siTCR-transduced CD8 + T cells showed good expansion after stimulation with WT1 peptide and maintained their antigen specificity. In contrast, WT1-coTCR-transduced CD8 + T cells showed rapid growth, but their WT1 specificity declined rapidly. A summary of this experiment using WT1-siTCR-transduced CD8 + T cells generated from 5 donors and WT1-coTCR-transduced CD8 + T cells generated from 3 donors is shown in Figure 2B .
We further confirmed the WT1 specificity and HLA-A*24:02 restriction of cytotoxicity mediated by WT1-siTCR-transduced CD8 + T cells that had been cultured and expanded 
Lysis of autologous leukemia cells and lack of damage to autologous hematopoietic progenitor cells by WT1-siTCR-transduced CTLs
For clinical application of adoptive T-cell therapy using WT1-TCR gene-engineered CTLs, it is essential to obtain evidence that autologous leukemia cells are indeed lysed and that autologous hematopoietic progenitor cells are not damaged by WT1-siTCR-transduced CTLs. We therefore performed cytotoxicity assays using WT1-siTCR-transduced CTLs as effector cells, and autologous leukemia cells from leukemia patients and hematopoietic progenitors from cord blood as target cells. As shown in Figure 4A , WT1-siTCR-transduced CTLs generated from peripheral blood CD8 + T cells of patients with leukemia exerted cytotoxicity against autologous leukemia cells. On the other hand, those generated from cord blood CD8 + T cells exerted no 
Furthermore, additional transfer of WT1-siTCR-transduced CTLs further significantly prolonged the survival period of K562-A*24:02-inoculated mice. Notably, no tumor formation was detected in mice during adoptive transfer of WT1-siTCR-transduced CTLs. These results clearly show the efficacy of adoptive T-cell therapy using WT1-siTCR-transduced CTLs for treatment of human leukemia.
No deteriorative effect of WT1-siTCR-transduced CTLs on engraftment and differentiation of autologous hematopoietic progenitor cells in humanized mice
Finally, we addressed the issue of whether WT1-siTCR-transduced CTLs exert an inhibitory effect on the proliferation and differentiation of normal hematopoietic progenitor cells, as it has been reported that WT1 expression is detectable in normal hematopoietic progenitor cells. 21, 22, 36 The hCB-CD34 + cells that had been preincubated with WT1-siTCR-transduced CTLs or control CTLs were transplanted into NOG mice.
Three months later, these mice were sacrificed and analyzed for engraftment and differentiation of human hematopoietic cells. HLA-A*24:02 appeared to be efficiently expressed in human blood cells that had proliferated in humanized mice (data not shown). Representative data for 3 experiments are shown in Figure 6A . CTLs never damage human CD34 + hematopoietic progenitor cells ( Figure 6B ).
Discussion
In our previous study, we developed a novel retroviral vector system that can express antigen-specific TCR more efficiently based on the concept of siRNA-targeting of the constant regions of the endogenous TCR-α and TCR-β genes and siRNA-resistant codon-optimization of exogenous TCR genes. 25 In order to apply the basic concept of Moreover, there appeared to be a significant correlation between clinical response and the persistence of infused T cells in the peripheral blood of patients.
9 Therefore, it would be important to maintain a sufficient number of TCR gene-engineered T cells with adequate antigen specificity in patients for a long period in order to achieve a good clinical response. In our present study, the antigen specificity of WT1-coTCR-transduced CTLs declined rapidly during culture, even though they were stimulated repeatedly with WT1 peptide. This might have been due to the formation of mispaired TCRs that had acquired non-specific reactivity. In contrast, WT1-siTCR-transduced CTLs appeared to be markedly expanded while maintaining WT1 specificity and showing enhanced WT1-specific cytotoxicity for more than 2 months as a result of repetitive stimulation with WT1 peptide. Recently, it has been reported that adoptively transferred gp100-specific murine T cells were expandable up suggesting a risk of bone marrow failure mediated by WT1-specific CTLs. Furthermore, the occurrence of severe leukocytopenia after WT1 peptide vaccination in 2 patients with myelodysplastic syndrome has been reported. 42 Therefore we examined in detail the inhibitory effect of WT1-siTCR-transduced CTLs on normal human hematopoiesis in a humanized mouse model. We clearly demonstrated that WT1-siTCR-transduced
CTLs never damaged normal human hematopoietic progenitor cells. There are three possible explanations for the mechanism underlying the resistance of normal hematopoietic progenitors to WT1-specific CTL-mediated cytotoxicity. The first is that the amount of WT1 expressed in normal hematopoietic progenitors is not enough to be recognized by CTLs. This possibility seems likely, since quantitative analysis has revealed that the expression level of WT1 mRNA in normal hematopoietic progenitor cells is relatively low compared with that in leukemia cells. 43, 44 The second is that normal hematopoietic progenitors have the potential to resist CTL-mediated cytotoxicity.
We previously reported that although the levels of WT1 expression in myeloma and lymphoma cells were almost the same, only myeloma cells were lysed efficiently by WT1-specific CTLs. The extent of membrane damage induced by purified perforin appeared to be significantly higher in myeloma cells than in lymphoma cells.
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Therefore, the susceptibility of membranes to perforin is an important factor determining the sensitivity of target cells to CTL-mediated cytotoxicity, and normal hematopoietic cells are relatively resistant to CTL-mediated granule exocytosis. The Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature.
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